Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases.
Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases.
复制标题
脂质修饰剂用于治疗肾小球疾病的用途。
DOI：
10.3390/jpm11080820
复制
发表时间：
2021-08-21
影响因子：
--
通讯作者：
Fornoni A
中科院分区：
文献类型：
--
作者：
Ge M;Merscher S;Fornoni A
虽然血脂异常与慢性肾脏疾病(CKD)有关，但它在肾病综合征(NS)中更常见，NS高脂血症的治疗指南基本上是基于观点的。除了循环脂质的作用外，越来越多的研究表明肾内脂质参与了肾小球疾病的进展，提示蛋白尿肾病可能是一种脂肪肾病，降低细胞内脂质可能是减缓CKD进展的一种新的治疗方法。在这篇综述中，我们总结了利用调脂药物降低肾实质脂质蓄积，预防或减轻肾损伤的最新进展。这篇综述中提到的药物根据其特定的靶点进行了分类，但它们也可能调节其他与脂质相关的途径。
Although dyslipidemia is associated with chronic kidney disease (CKD), it is more common in nephrotic syndrome (NS), and guidelines for the management of hyperlipidemia in NS are largely opinion-based. In addition to the role of circulating lipids, an increasing number of studies suggest that intrarenal lipids contribute to the progression of glomerular diseases, indicating that proteinuric kidney diseases may be a form of “fatty kidney disease” and that reducing intracellular lipids could represent a new therapeutic approach to slow the progression of CKD. In this review, we summarize recent progress made in the utilization of lipid-modifying agents to lower renal parenchymal lipid accumulation and to prevent or reduce kidney injury. The agents mentioned in this review are categorized according to their specific targets, but they may also regulate other lipid-relevant pathways.
登录
查看更多内容
影响因子：
9.8
作者：
Chehade, Joe M.;Alcalde, Rosalyn;Haas, Michael J.
通讯作者：
Haas, Michael J.
影响因子：
4.8
作者：
Björkegren, J;Véniant, M;Young, SG
通讯作者：
Young, SG
影响因子：
4.8
作者：
Duchateau, PN;Pullinger, CR;Kane, JP
通讯作者：
Kane, JP
影响因子：
82.9
作者：
Chawla, A;Barak, Y;Evans, RM
通讯作者：
Evans, RM
影响因子：
5.6
作者：
Costa, Raquel;Rodrigues, Ilda;Soares, Raquel
通讯作者：
Soares, Raquel